Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Beth Dudley

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8464-6014; OpenAlex author ID A5090191635. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
64
Papers, trials and grants by year

2018: 2 papers · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. Cigarette smoking drives earlier development of pancreatic adenocarcinoma among carriers of hereditary pancreatic cancer susceptibility genes. Co-author DOI 10.1016/j.pan.2026.05.004↗
  2. Improving uptake of germline genetic testing amongst individuals at high-risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/tgh-24-152↗
  3. The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration. First author DOI 10.1002/cncr.35383↗
  4. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  5. Pancreatic Cancer Surveillance and Novel Strategies for Screening. Co-author DOI 10.1016/j.giec.2021.08.008↗
  6. COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Co-author DOI 10.1016/j.pan.2021.04.005↗
  7. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  8. Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.32077↗
  9. Pancreatic Cancer Surveillance: Who, When, and How. Co-author DOI 10.1007/s11938-019-00247-0↗
  10. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy. Co-author DOI 10.1002/cncr.31242↗
  11. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.31628↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Randall E. Brand · 8 shared papers, 2018–2026 · strength 1.29
  2. Bryson W. Katona · 3 shared papers, 2021–2025 · strength 0.72
  3. Eve Karloski · 5 shared papers, 2018–2026 · strength 0.66
  4. Aatur Dilip Singhi · 2 shared papers, 2018–2026 · strength 0.37
  5. Amer H. Zureikat · 2 shared papers, 2018–2026 · strength 0.34
  6. Fay Kastrinos · 3 shared papers, 2021–2024 · strength 0.33
  7. Christine Worthington · 1 shared paper, 2026 · strength 0.28
  8. Lynette M. Smith · 1 shared paper, 2026 · strength 0.28
  9. Timothy D. Shu · 1 shared paper, 2026 · strength 0.28
  10. Alessandro Paniccia · 1 shared paper, 2026 · strength 0.28
  11. Jessica N. Everett · 2 shared papers, 2021–2024 · strength 0.23
  12. Diane M. Simeone · 2 shared papers, 2021–2024 · strength 0.23
  13. Sonia S. Kupfer · 2 shared papers, 2021–2024 · strength 0.23
  14. Elana Levinson · 1 shared paper, 2024 · strength 0.15
  15. Heather Hampel · 1 shared paper, 2024 · strength 0.15
  16. Marta Puzzono · 1 shared paper, 2024 · strength 0.15
  17. Christine M. Drogan · 1 shared paper, 2024 · strength 0.15
  18. Giulia Martina Cavestro · 1 shared paper, 2024 · strength 0.15
  19. Nathan Bahary · 2 shared papers, 2018 · strength 0.15
  20. Mary Linton B. Peters · 2 shared papers, 2018–2019 · strength 0.14
  21. Nadine Tung · 2 shared papers, 2018–2019 · strength 0.14
  22. Erkut Hasan Borazanci · 2 shared papers, 2018–2019 · strength 0.14
  23. Marcia Irene Canto · 1 shared paper, 2021 · strength 0.10
  24. Ankit Chhoda · 1 shared paper, 2021 · strength 0.10
  25. Umar Hayat · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.